IP Verse

Deva Holding competitive analysis

Explore patent oppositions filed by Deva Holding against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jun 18, 2026

Patent Number	Title	Applicant	Opposition Date
EP3689365	Use Of Long-Acting Glp-1 Peptides	NOVO NORDISK	Apr 28, 2026
EP3377534	Treatment Of Lung Cancer Using A Combination Of An Anti-Pd-1 Antibody And An Anti-Ctla-4 Antibody	BRISTOL MYERS SQUIBB	Mar 11, 2026
EP4338805	Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy	AMARIN PHARMACEUTICALS IRELAND	Feb 26, 2026
EP4342546	Methods Of Reducing The Risk Of A Cardiovascular Event In A Subject On Statin Therapy	AMARIN PHARMACEUTICALS IRELAND	Feb 26, 2026
EP4218732	Tablets Comprising Eltrombopag Olamine	NOVARTIS	Dec 16, 2025
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jul 22, 2025

Discover the latest PTAB cases involving Deva Holding, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Deva Holding with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jun 18, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
DEVA HOLDING	6	-	-	-
AMARIN PHARMACEUTICALS IRELAND	-	19	-	1
BRISTOL MYERS SQUIBB	-	74	-	8
NOVARTIS	6	441	-	21